Claims for Patent: 7,273,608

Summary for Patent: 7,273,608

Title:	Humanized anti-CEA T84.66 antibody and uses thereof
Abstract:	Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.
Inventor(s):	Yazaki; Paul J. (Glendale, CA), Sherman; Mark A. (Pasadena, CA), Shively; John E. (Arcadia, CA), Raubitschek; Andrew A. (San Marino, CA), Wu; Anna M. (Sherman Oaks, CA)
Assignee:	City of Hope (Duarte, CA)
Application Number:	11/077,978
Patent Claims:	1. A humanized antibody comprising; a) a light chain variable region comprising the amino acid sequence of SEQ ID NO:1 wherein the L4, L24-L34, L50-L56, L66-L69, and L89-L97 residues of trastuzumab variable light chain (residues 4, 24-34, 50-56, 66-69, and 89-97, respectively, of SEQ ID NO:6) have been replaced with the corresponding residues from murine T84.66 monoclonal antibody variable light chain (residues 4, 24-38, 54-60, 70-73, and 93-101, respectively, of SEQ ID NO:4); and b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:2 wherein the H30-H35, H50-H58, and H93-H102 residues of trastuzumab variable heavy chain (residues 30-35, 50-59, and 97-109, respectively, of SEQ ID NO:7) have been replaced with the corresponding residues from the murine T84.66 monoclonal antibody variable heavy chain (residues 30-35, 50-59, and 97-110, respectively of SEQ ID NO:5) 2. The humanized antibody of claim 1, further comprising a conjugate. 3. The humanized antibody of claim 2, where said conjugate is a radiolabel. 4. A cell line expressing the humanized antibody of claim 1. 5. The cell line of claim 4, wherein said cell line is mammalian. 6. The humanized antibody of claim 1, further comprising: a) a human light chain constant region; and b) a human heavy chain constant region.

Details for Patent 7,273,608

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2024-03-11
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2024-03-11
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2024-03-11